Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephan Stilgenbauer

Showing results (341-350 of 466) with videos related to

Pageof 47
Sort By:
Blood|February 2, 2022
Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemiaHenriette Huber, Simone Edenhofer, Julia von Tresckow, et al.
Leukemia|June 25, 2021
Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendationsWilliam G Wierda, Andrew Rawstron, Florence Cymbalista, et al.
The Lancet. Oncology|September 18, 2016
Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre studySusan O'Brien, Jeffrey A Jones, Steven E Coutre, et al.
Blood|March 25, 2020
Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclaxEugen Tausch, Christof Schneider, Sandra Robrecht, et al.
The Lancet. Oncology|May 15, 2016
Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 studyStephan Stilgenbauer, Barbara Eichhorst, Johannes Schetelig, et al.
The New England Journal of Medicine|January 10, 2014
Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditionsValentin Goede, Kirsten Fischer, Raymonde Busch, et al.
The Lancet. Haematology|August 2, 2016
High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trialGerald Illerhaus, Benjamin Kasenda, Gabriele Ihorst, et al.
Leukemia|March 11, 2025
Subgrouping germinal center-derived B-cell lymphomas based on machine learning-deduced DNA methylation modulesSelina Glaser, Anja Fischer, Juan Emilio Martínez-Manjón, et al.
Nature Medicine|December 9, 2023
Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trialOthman Al-Sawaf, Rudy Ligtvoet, Sandra Robrecht, et al.
The Lancet. Haematology|September 17, 2017
Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 studyAnna Maria Fink, Jasmin Bahlo, Sandra Robrecht, et al.
Pageof 47

Showing results (341-350 of 466) with videos related to

Sort By:
Pageof 47
Blood|February 2, 2022
Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemiaHenriette Huber, Simone Edenhofer, Julia von Tresckow, et al.
Leukemia|June 25, 2021
Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendationsWilliam G Wierda, Andrew Rawstron, Florence Cymbalista, et al.
The Lancet. Oncology|September 18, 2016
Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre studySusan O'Brien, Jeffrey A Jones, Steven E Coutre, et al.
Blood|March 25, 2020
Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclaxEugen Tausch, Christof Schneider, Sandra Robrecht, et al.
The Lancet. Oncology|May 15, 2016
Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 studyStephan Stilgenbauer, Barbara Eichhorst, Johannes Schetelig, et al.
The New England Journal of Medicine|January 10, 2014
Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditionsValentin Goede, Kirsten Fischer, Raymonde Busch, et al.
The Lancet. Haematology|August 2, 2016
High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trialGerald Illerhaus, Benjamin Kasenda, Gabriele Ihorst, et al.
Leukemia|March 11, 2025
Subgrouping germinal center-derived B-cell lymphomas based on machine learning-deduced DNA methylation modulesSelina Glaser, Anja Fischer, Juan Emilio Martínez-Manjón, et al.
Nature Medicine|December 9, 2023
Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trialOthman Al-Sawaf, Rudy Ligtvoet, Sandra Robrecht, et al.
The Lancet. Haematology|September 17, 2017
Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 studyAnna Maria Fink, Jasmin Bahlo, Sandra Robrecht, et al.
Pageof 47